fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Amiloride HCL

All products: general benefit

Midamor · DIN 02249510 · 5 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Midamor · DIN 02249510 Manufacturer: A A Pharma Inc.; listing date 2004-08-11 Health Canada: Marketed since 2011-04-04 · brand MIDAMOR · ATC C03DB01 AMILORIDE · form Tablet · route Oral · ingredients AMILORIDE HYDROCHLORIDE 5.0 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Midamor: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3297). What the ministry pays, not the patient.

Ministry pays: $0.3297 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02249510)

Source record
DIN 02249510: Midamor Raw flags: chronicUseMed=Y, sec3=Y Item: 402800031; group id 555; item number 1493; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3297; ministry $0.3297 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02249510 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73433
Shortage status: active shortage (reported September 15, 2026, estimated to end November 6, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249510
Shortage record checked October 6, 2026

Other products in the same Health Canada class (C03D): coverage varies; not interchangeable

  • Spironolactone (Aldactone): general benefit
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: METOLAZONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE, SPIRONOLACTONE 40:28 Diuretics

SPIRONOLACTONE

· 8 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (6) · strengths: 25mg, 100mg · Tab

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications MIDAMOR (amiloride hydrochloride tablets) is indicated: • For use alone or concomitantly with thiazide diuretics or other kaliuretic-diuretic agents in the treatment of patients with cirrhosis of the liver with ascites and edema. • As an adjunct to thiazide diuretics or other kaliuretic-diuretic agents for the treatment of edema of cardiac origin or of hypertension in patients who have hypokalemia, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, patients in whom adequate dietary intake of potassium is not feasible, or patients with cardiac arrhythmias. Use in Hepatic Cirrhosis with Ascites and Edema MIDAMOR used alone may provide satisfactory diuresis with diminished potassium loss and with a reduced risk of metabolic alkalosis. In resistant cases MIDAMOR may be used with kaliuretic-diuretic agents to help produce satisfactory diuresis, while maintaining a more balanced serum electrolyte pattern. As with all therapy for the ascites of hepatic cirrhosis, gradual weight loss and avoidance of electrolyte imbalance are the chief objectives. See 7 WARNINGS AND PRECAUT… https://pdf.hres.ca/dpd_pm/00080786.PDF PM date: 2025-06-10 Source product: MIDAMOR; DIN 02249510; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Midamor · DIN 02249510 Shortage status: active shortage (reported 2026-09-15, estimated to end 2026-11-06, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02249510

Check this DIN again